1. |
Bonis PA, Trikalinos TA, Chung M, et al. Hereditary non-polyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 2007; 150:1-180.
|
2. |
Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008; 10:301-7.
|
3. |
Oba M, Miwa K, Fujimura T, et al. Chemoprevention of glandular stomach carcinogenesis through duodenogas-tric reflux in rats by a COX-2 inhibitor. Int J Cancer 2008; 123:1491-8.
|
4. |
Bresalier RS. Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story). Curr Opin Gastroenterology 2007; 23:44-7.
|
5. |
Chew MH, Koh PK, Ng KH, et al. Phenotypic characteristics of hereditary non-polyposis colorectal cancer by the Am-sterdam criteria: an Asian perspective. ANZ J Surg 2008; 78:556-60.
|
6. |
Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Col-laborative group on HNPCC. Gastroenterology 1999; 116:1453-6.
|
7. |
Sheng JQ, Chan TL, Chan YW, et al. Microsatellite insta-bility and novel mismatch repair gene mutations in northern Chinese population with hereditary non-poly-posis colorectal cancer. Chin J Dig Dis 2006; 7:197-205.
|
8. |
Lim SC, Lee TB, Choi CH, et al. Expression of cyclooxy-genase-2 and its relationship to p53 accumulation in co-lorectal cancers. Yonsei Med J 2007; 48:495-501.
|
9. |
Ferrario A, Fisher AM, Rucker N, et al. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005; 65:9473-8.
|
10 |
Yim HW, Jong HS, Kim TY, et al. Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res 2005; 65:1952-60.
|
11 |
Brown JR, DuBois RN. COX-2: a molecular target for co-lorectal cancer prevention. J Clin Oncol 2005; 23:2840- 55.
|
12 |
Sheng JQ, Li SR, Yang XY, et al. Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis. Zhonghua Yi Xue Za Zhi 2006; 86:526-9.
|
13 |
Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, et al. Re-duced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998; 58:5473-7.
|
14 |
Song WQ, Han CL, Zhou BJ, et al. Relationship between COX-2 expression and hMLH1, hMSH2 expression in co-lorectal carcinoma. World Chin J Digestol 2005; 13:105-9.
|